GUBamy: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides →
📌TL;DR
- •Community protocols detailed below
- •Evidence level: Anecdotal Reports
- •See community reports below
- •Stacking patterns detailed below
Sources
- Reddit r/Peptides|Amylin analog and DACRA obesity pipeline discussions(accessed 2026-02-16)
- Reddit r/loseit|Non-GLP-1 obesity drug pipeline discussions(accessed 2026-02-16)
Community Evidence Overview#
This page documents the community evidence landscape for GUBamy (GUB014295). This is not clinical evidence and should not be used as medical guidance.
GUBamy has no community self-experimenter data. It is an early-stage investigational compound currently in Phase 1 clinical trials.
Why There Is No Community Data#
Very Early Stage Development#
GUBamy is in Phase 1 multiple ascending dose (MAD) trials, representing one of the earliest stages of clinical development. The compound has only been tested in a small number of clinical trial participants, and its safety profile in humans is still being established.
Proprietary Pharmaceutical Development#
GUBamy was developed by Gubra, a Danish biopharmaceutical company, and licensed to AbbVie in a deal worth up to $350 million. The compound's proprietary sequence has not been publicly disclosed, making independent synthesis impossible. It is exclusively available within controlled clinical trial settings.
Non-GLP-1 Mechanism Interest#
While GUBamy itself has no community data, the broader concept of amylin-based weight loss is generating community interest. The success of pramlintide (Symlin) and the promising results of cagrilintide have drawn attention to amylin receptor agonism as a complementary or alternative approach to GLP-1-based therapies.
Pipeline Context#
GUBamy is one of several amylin analogs in development for obesity, competing with petrelintide (Zealand Pharma/Roche) and cagrilintide (Novo Nordisk). The "non-GLP-1" weight loss space is increasingly watched by community members who have experienced GI tolerability issues with GLP-1 agonists.
Related Reading#
- GUBamy Research & Clinical Studies
- GUBamy Molecular Profile
- Cagrilintide - More advanced amylin analog
- Petrelintide - Competing amylin analog
- Pramlintide - FDA-approved amylin analog
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles · 30+ comparisons · 18 research tools
Frequently Asked Questions About GUBamy
Is GUBamy available for purchase?
No. GUBamy (GUB014295) is an early-stage investigational compound developed by Gubra and licensed to AbbVie. It is currently in Phase 1 clinical trials and is not available through any pharmacy or peptide vendor. It is years away from potential market availability.
What makes GUBamy different from other obesity drugs?
GUBamy is a dual amylin and calcitonin receptor agonist (DACRA), which represents a non-GLP-1 mechanism for weight loss. Unlike GLP-1 agonists like semaglutide, it works through amylin signaling to reduce appetite and promote satiety. Its 11-day half-life supports once-weekly dosing. Phase 1 data showed 7.77% weight loss in just 43 days.
Could GUBamy be combined with GLP-1 agonists?
The combination of amylin-based compounds with GLP-1 agonists is an active area of research. CagriSema (cagrilintide + semaglutide) is the most advanced example of this combination approach. Whether GUBamy specifically will be studied in combination with GLP-1 agonists depends on AbbVie's clinical development strategy.
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.